<code id='F72B6E2B90'></code><style id='F72B6E2B90'></style>
    • <acronym id='F72B6E2B90'></acronym>
      <center id='F72B6E2B90'><center id='F72B6E2B90'><tfoot id='F72B6E2B90'></tfoot></center><abbr id='F72B6E2B90'><dir id='F72B6E2B90'><tfoot id='F72B6E2B90'></tfoot><noframes id='F72B6E2B90'>

    • <optgroup id='F72B6E2B90'><strike id='F72B6E2B90'><sup id='F72B6E2B90'></sup></strike><code id='F72B6E2B90'></code></optgroup>
        1. <b id='F72B6E2B90'><label id='F72B6E2B90'><select id='F72B6E2B90'><dt id='F72B6E2B90'><span id='F72B6E2B90'></span></dt></select></label></b><u id='F72B6E2B90'></u>
          <i id='F72B6E2B90'><strike id='F72B6E2B90'><tt id='F72B6E2B90'><pre id='F72B6E2B90'></pre></tt></strike></i>

          fashion

          fashion

          author:entertainment    Page View:448
          Ruby Wallau for STAT

          Sarepta Therapeutics said Monday afternoon that its gene therapy for Duchenne muscular dystrophy failed to improve muscle function compared to a placebo in a large clinical trial — likely a major disappointment for patients and doctors who have been desperately awaiting the treatment for years.

          The company said all patients in the study improved and that secondary measurements indicated the drug was having an effect. Nevertheless, the results are likely to raise questions about whether the Food and Drug Administration will expand access to the medicine.

          advertisement

          Trading in Sarepta shares was halted at $107 with the release of the study results.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          focus

          ChatGPT in medicine: STAT answers readers' burning questions
          ChatGPT in medicine: STAT answers readers' burning questions

          MikeReddyforSTATArtificialintelligenceisoftendescribedasablackbox:anunknowable,mysteriousforcethatop

          read more
          Advances in CAR
          Advances in CAR

          AdamFeuerstein,upperleft,moderatedapanelwith,clockwise,DavidChangofAllogeneTherapeutics,RachelHaurwi

          read more
          George Santos makes 1st court appearance after pleading not guilty to 13 counts
          George Santos makes 1st court appearance after pleading not guilty to 13 counts

          1:57GeorgeSantosarrivesatfederalcourtJune30,2023,inCentralIslip,N.Y.JohnMinchillo/APRep.GeorgeSantos

          read more

          Readout Newsletter: Bayer study halts, Carmot to IPO, and more

          KenaBetancur/GettyImagesWanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetourbi